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Abstract
OMERACT is the acronym for an international, informally organized network initiated in 1992
aimed at improving outcome measurement in rheumatology. Chaired by an executive committee,
it organizes consensus conferences in a 2-yearly cycle that circles the globe. Data driven
recommendations are prepared and updated by expert working groups. Recommendations include
core sets of measures for most of the major rheumatologic conditions. Since 2002 patients have
been actively engaged in the process.
What is OMERACT?
"Clinical trials are only as credible as their endpoints" [1].
OMERACT strives to improve endpoint outcome meas-
urement through a data driven, iterative alignment proc-
ess as described below. The key characteristics of
OMERACT include a commitment to the data-driven
interactive development of a majority alignment across
relevant stakeholder groups on determining relevant
health outcome domains and endorsing valid, responsive,
feasible health outcome measures/scales in patients with
musculoskeletal conditions.
The first conference on rheumatoid arthritis was held in
Maastricht, the Netherlands in 1992. The motivation for
this were discussions between two of the authors, [MB
and PT], comparing the outcomes used in European clin-
ical trials of rheumatoid arthritis with that of North Amer-
ican clinical trials, and noting that they used different
endpoints. This made it extremely difficult to compare
and combine in meta-analyses. One of the authors had
had a good experience with the nominal group technique
to build consensus on some controversial issues around
developing a patient preference health status measure [2]
and thus suggested using this to develop agreement on a
core set of outcomes for RA Clinical Trials.
The first conference had 3 goals:
(1) To attempt to obtain agreement on the minimum
number of outcome measures to be included in all RA
clinical trials. This was implemented by a preconference
questionnaire, presentation of the evidence on their valid-
ity, both small group and plenary discussions on their per-
formance in trials and in individual patients, and then by
voting using an electronic voting procedure.
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(2) To review the range of magnitude of differences
judged to be clinically important by experienced clini-
cians and clinical investigators. This was implemented by
a baseline questionnaire and rank ordering of a series of
clinical trials and individual patient scenarios, using a
nominal group technique.
(3) To review the extent to which experienced clinicians
and clinical investigators feel that aggregate measures
(indices) are useful in the assessment of trials and individ-
ual patients. This was implemented by presentation of the
concepts behind a variety of examples of indices, by ques-
tionnaire and a scenario ranking exercise incorporating
the results of 3 indices.
The term OMERACT was originally established to mean
"Outcome Measures in Rheumatoid Arthritis Clinical Tri-
als". Since then the OMERACT initiative has turned into
an international informal network, with working groups
and gatherings interested in outcome measurement across
the spectrum of rheumatology intervention studies. The
acronym has therefore been broadened to now stand for
'Outcome Measures in Rheumatology'.
OMERACT has a 5 member Organizing Committee with
members from three continents; it has a 15-member Sci-
entific Advisory Committee composed of international
opinion leaders from nine countries. More information
on OMERACT is available at our website [3], including
full proceedings from the recent conferences, and excerpts
from earlier proceedings, all of which are freely down-
loadable.
What does OMERACT do?
Agreement regarding the use of standardized endpoints in
randomized controlled trials and longitudinal observa-
tional studies is extremely important. Their use facilitates
comparisons of outcomes across studies to provide the
best estimates of benefit and safety of therapeutic inter-
ventions across differing patient populations. To improve
outcome measurement, OMERACT organizes conferences
that take place every two years and rotate around the
globe. For these conferences, topics of interest are pre-
pared by groups of experts. These topics are then prepared
for the conference by literature review and specification of
the points for discussion. Most topics are discussed in
workshop format, where the aim is to make explicit the
areas of agreement and disagreement, and to prioritize the
research agenda. In several areas, the group has taken the
lead in actually performing the necessary research to bring
back to the conference.
Recently, special interest group meetings have emerged
alongside OMERACT conferences to speed up the work.
When enough data is available, a full module is organized
with the intention to come to consensus on guidelines. In
addition, OMERACT hosts a discussion group on out-
come measures. OMERACT works under the aegis of the
International League for Rheumatology (ILAR), the aus-
pices of the World Health Organization (WHO), and is
now in the process of a formal affiliation with the Bone
and Joint Decade. OMERACT is linked to the Cochrane
Collaboration Musculoskeletal Review Group, where the
outcomes endorsed by OMERACT are recommended for
use in Cochrane Systematic Reviews [4,5].
How does OMERACT work?
To reach consensus over what should be measured, and
how, i.e., what measures are applicable in trials for each
clinical indication, OMERACT has developed the follow-
ing procedure. First, the organizing committee polls
experts and opinion leaders to generate interest in the
topic at hand. These individuals then form a committee to
guide the subsequent process. From the general domains
of health status defined by the "D's" (Discomfort, Disabil-
ity, Dollar Cost, Death), specific domains are formulated
for the topic in question. In each domain, measures are
collected and tested for their applicability. The domains
and the applicable measures form the basis for the con-
sensus guidelines. The process is data-driven and iterative,
and has evolved over the past 14 years. Although not
needed when OMERACT was small and the same individ-
uals were involved, as OMERACT has grown and new
individuals take on the leadership of taskforces, we have
found it helps to break down the process into the different
stages of Special Interest Groups, Workshops and Mod-
ules. One or more of the executive continue to be actively
involved in each task force.
Currently, an initiative starts as a Special Interest Group. A
small group of experts initiates the research agenda by lit-
erature reviews and validation studies. At the conference,
in informal discussions, the research agenda is prioritized
and tasks are distributed among interested parties. The
next step is a Workshop; where studies are presented that
help the formulation and selection of the domains. Again,
agreement is reached on priorities in research to be per-
formed. The final step is the Module in which evidence
(both from literature and from targeted studies) is pre-
sented, and final selection of measures can take place.
Both in Workshops and in Modules, plenary presenta-
tions are complemented by small group sessions where
participants express their views and preferences.
These views are brought back to the plenary session,
where a final consensus is formulated with the help of
interactive voting using electronic touchpads. In Modules,
consensus implies agreement on domains or measures;
and in Workshops it means the formulation of a research
agenda in areas where data-driven decisions cannot beTrials 2007, 8:38 http://www.trialsjournal.com/content/8/1/38
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made. The process is iterative, in that guidelines are for-
ever "preliminary" based on the assumption that future
data (sometimes a direct result of the research agenda)
will serve to refine or modify them. The work needed to
justify a module with voting can be fast tracked and
achieved within 12 months if there is sufficient existing
data on the performance of the instruments measuring the
selected attributes. The new staging of starting with SIGs,
with criteria for moving to a Workshop, and the addi-
tional requirements to warrant a Module, all reflect the
expectation that the process can take up to 6 years or more
– this is has been the case with outcomes for adverse
effects which has been a focus at every OMERACT meeting
since the second OMERACT in 1994.
When is a measure "endorsed by OMERACT"?
A measure is "endorsed" when it passes the OMERACT Fil-
ter in its intended setting.
The OMERACT Filter has three component criteria: Truth,
Discrimination, and Feasibility. Each component criteria
represents a question to be answered of the measure, in
each of its intended settings:
1. Truth: is the measure truthful, does it measure what it
intends to measure? Is the result unbiased and relevant?
This criterion captures the issues of face, content, con-
struct and criterion validity.
2. Discrimination: does the measure discriminate
between situations that are of interest? The situations can
be states at one time (for classification or prognosis) or
states at different times (to measure change). This crite-
rion captures the issues of reliability and sensitivity to
change.
3. Feasibility: can the measure be applied easily, given
constraints of time, money, and interpretability? This cri-
terion addresses the pragmatic reality of the use of the
measure, one that may be decisive in determining a meas-
ure's success.
What has been achieved?
These 8 OMERACT conferences have succeeded in achiev-
ing consensus on core sets of measures for rheumatoid
arthritis, osteoarthritis and osteoporosis, psoriasis/psori-
atic arthritis [GRAPPA], on psychosocial measures, core
set of data for cost-effectiveness evaluations. Taskforces
are ongoing in working towards consensus in Surrogate
Endpoints in Rheumatology Trials, and Psoriatic Arthritis.
Workshops were held on MRI in Ankylosing Spondylitis
(AS), Fibromyalgia, Fatigue, Repair in RA, Radiographs/
Joint Space Narrowing, Vasculitis, Drug Safety, Sclero-
derma, Work Productivity, Item Response Theory & Com-
puter Adaptive Testing, Gout, Low Back Pain, Baseline
State in RA, Economic Reference Case in AS, Virtual total
articular replacement as outcome, Ultrasound, Synovial
Tissue, Chemical Biomarkers, MRI in inflammatory
arthritis, Single joint response, the Effective Consumer
Scale.
The size of the conference has steadily grown from around
80 attendees to 250 attendees at OMERACT 8 – in part
due the importance of having leaders in each topic from
the Americas, Europe and Australasia and a critical mass
of attendees with expertise in the area. Meetings are held
intermittently at the World Health Organization to ratify
these core sets.
Impact of OMERACT
Omeract is only one of many initiatives to increase the
standardization of outcomes, (e.g. the regular revisions to
guidance documents of the regulatory agencies) and sees
itself as supporting and facilitating such activities. It is rea-
sonable to argue that OMERACT has provided a key
forum for discussions between the different stakeholders,
with protected time to focus on this area. Although not
quantified, there is little dispute that the number of differ-
ent primary outcomes has markedly dropped and the
OMERACT core sets have been adopted by many other
organizations, often being relabeled for their constitu-
ency. The Cochrane author guidelines for the Cochrane
musculoskeletal Review Group recommend their use.
With few exceptions, the same people have been involved
in the development of the American College of Rheuma-
tology [ACR] and European League Against Rheumatism
[EULAR]; thus the measures adopted by these organiza-
tions are very similar.
The OMERACT process has been emulated by two other
independent groups: one working in the field of chronic
juvenile arthritis, and one in ankylosing spondylitis. The
former group first developed a core set and has continued
with response criteria, closely mimicking the process fol-
lowed by the American College of Rheumatology and
OMERACT for adult rheumatoid arthritis. The latter group
initially formulated a core set for ankylosing spondylitis,
but has now decided to bring their deliberations under the
OMERACT umbrella.
Outside of rheumatology, members of the executive com-
mittee have lectured on the OMERACT methodology at
sessions at the American College of Rheumatology, and
various other meetings for experts in community genetics,
gastroenterology (non-ulcer dyspepsia), health econom-
ics, intensive care medicine, MRI imaging, neurology
(neuropathies), and pain measures.Trials 2007, 8:38 http://www.trialsjournal.com/content/8/1/38
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Two meetings were held at the World Health Organiza-
tion headquarters in Geneva, cosponsored by ILAR. At the
first in 1993, the core set agreed upon at OMERACT 1 was
ratified. At the second in 2000, the core sets and recom-
mendations arising out of OMERACT 2–4 were ratified.
OMERACT 5 was the first to include a "Young Investiga-
tor's Day," thanks to sponsorship of the European Com-
munity (Fifth framework). This allowed active young
investigators to present recent and ongoing work and be
critically appraised by OMERACT faculty. After this day
these investigators became full participants in the confer-
ence. Funding permitting, we hope to make this a perma-
nent feature of OMERACT conferences.
A small workshop of economics experts was held in New
York early in 2001 to lay the groundwork for the module
at OMERACT 6. The objective of that meeting was to
develop a "reference case" for rheumatology as the first
applied version of the generic reference case approach rec-
ommended by the US Public Health Service appointed
Panel on Cost-Effectiveness in Health and Medicine. This
comprises a proposed set of minimum criteria that all eco-
nomic analyses should include in order to allow compa-
rability across studies in the following categories: model
horizon, duration of treatment, extrapolation beyond trial
duration, modeling beyond trial duration, synthesis of
comparisons where clinical trials do not exist, outcome
measures, valuation of health (e.g. QALYs), classification
and reporting of adverse events, discontinuation of treat-
ment, therapeutic strategies, population risk stratification,
and resource use. This was applied to rheumatoid arthritis
at OMERACT 6 and for osteoarthritis and osteoporosis at
an NIH funded meeting at the Mayo clinic in April 2003.
Funded by EULAR, in 2005 the OMERACT MRI group
completed an atlas of MRI images as a special supplement
to the Annals of Rheumatic Diseases: The "EULAR-OMER-
ACT rheumatoid arthritis MRI references image atlas".
This atlas allows training and further propagation of the
reading method endorsed at OMERACT 6.
The evolution of OMERACT
The governance is evolving to accommodate the increased
size of OMERACT, whilst retaining the 'spirit' and special
aspects of this informal organization – these include
respectful collaboration across all disciplines/sectors,
good communication, open decision-making, teamwork,
avoidance of duplication, minimal bureaucracy, explicit
handling of potential conflicts of interest, continuity,
international representation, and wide participation. At
OMERACT 8 it was agreed to establish a Steering Group
that expands the Executive to include representatives of
the leaders of past Omeract Modules/Workshops/SIGs
and other stakeholders; for example, lower/middle
income countries, major associations, patients, practition-
ers, private sector. The remit is for this Steering Group to
assume overall responsibility for overseeing the develop-
ment and implementation of policy affecting OMERACT.
The Steering Group will have a legal responsibility as the
Board of Directors for OMERACT as a registered not-for-
profit organisation in Canada. The draft objectives
include a) To ensure a systematic mechanism for input
from the over-50 individuals who have provided leader-
ship of the many OMERACT groups who have held events
at the eight OMERACT meetings so far; b) To provide a
forum for discussion of policy with minutes to ensure
transparency, whilst retaining the agility of being 'infor-
mal'.
Since OMERACT 6, patients have been actively involved
in the OMERACT process. The patient group has been
mentored by John Kirwan (Bristol, UK), but has devel-
oped into an independent 'pressure group' within the
OMERACT initiative. At OMERACT 8 they elected their
own executive of 6 individuals representing 3 continents,
with a Chair who will represent them on the new Steering
Group described above. The group publishes a newsletter
and has produced an OMERACT glossary for the benefit of
patients, but eminently useful for professionals involved
in OMERACT as well.
Funding: OMERACT is based on the voluntary contribu-
tions of participants – a substantial commitment on
probono time is required of the group leading each task
force over several years to complete the stages to getting
the majority vote on a core set. Support for the confer-
ences has been provided by a mixture of industry, univer-
sity and governmental support. Fellowship support from
trainees has been provided through grants from the Euro-
pean Community and EULAR.
Conclusion
OMERACT appears to be valued by both the 'producers'
and the 'users' of evidence from rigorous clinical trials and
observational studies. These efforts to identify, standard-
ize and collect validated outcome measures, as well as def-
initions of minimal clinically important differences
[MCID] in patient reported outcomes, have helped to
interpret results from randomized controlled trials to eve-
ryday clinical practice. They have also facilitated defini-
tions of clinically meaningful changes, especially in the
context of meta-analyses conducted under the Cochrane
Collaboration.
Consensus processes conducted within OMERACT facili-
tate efforts to define and measure improvements in health
outcomes across broad populations with musculoskeletal
diseases. Linking efforts under the "OMERACT umbrella"
with the Bone and Joint Decade initiative will help to
identify important unmet needs addressing impairmentsTrials 2007, 8:38 http://www.trialsjournal.com/content/8/1/38
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in physical function and health related quality of life
shared by most individuals suffering from chronic inflam-
matory and/or arthritic conditions.
We should be delighted to compare and contrast this
experience in musculoskeletal disorders with other
approaches in the same and other fields; however, it does
take time – it is important to emphasize that groups wish-
ing to make similar progress in other fields should not
expect to achieve consensus or have an impact in the short
term
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